Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

The company plans to seek regulatory approval for the revolutionary weight loss treatment by the end of the year.

Eli Lilly’s new obesity and diabetes pill has shown it can lower blood sugar and aid weight loss in a late-stage trial, ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...

The analyst highlights that Lilly’s drugs, Mounjaro and Zepbound, will likely keep gaining U.S. market share from Novo ...

Novo Nordisk A/S (NYSE:NVO) shares fell as much as 8% in Thursday trading after news emerged about a competitor’s successful drug trial.

Several hundred units of counterfeit Ozempic (semaglutide) injection 1 mg have been found in the United States. The FDA ...

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a ...

XENICAL remains a well-recognized option for obesity management, offering clinically significant weight loss and metabolic benefits through a unique fat-blocking mechanism. However, its high ...

XENICAL remains a well-recognized option for obesity management, offering clinically significant weight loss and metabolic ...